US SEC Filings Daily Market Digest — August 12, 2026

12-08-2026

Mainstay Capital Management LLC filed its quarterly 13F-HR report for the period ending June 30, 2026, disclosing 144 holdings with a total market value of approximately $1.351 billion. The portfolio is heavily weighted toward ETFs and precious metals funds, with top positions including the iShares Silver Trust ($77.7M), iShares MSCI USA Value ETF ($117.6M), and the SPDR S&P 500 Growth ETF ($102.0M). The filing reflects a diversified, income- and value-oriented strategy with significant exposure to gold, silver, and dividend-focused funds.

• · The portfolio includes 144 holdings with a total value of $1,351,204,304.
• · Top equity positions include Caterpillar ($4.4M), Exxon Mobil ($4.3M), Southern Co. ($4.1M), Cisco ($4.0M), JPMorgan Chase ($3.8M), and Taiwan Semiconductor ($3.5M).
• · Significant precious metals exposure: iShares Silver Trust ($77.7M), iShares Gold Trust ($61.0M), Global X Silver ETF ($21.5M), Amplify Junior Silver Mine ETF ($18.7M), VanEck Gold Miners ETF ($15.5M), VanEck Junior Gold Miners ETF ($11.1M), Aberdeen Precious Metals Basket ($10.3M), SPDR Gold Trust ($3.9M).
• · Other notable holdings include Lam Research ($8.6M), NVIDIA ($7.6M), Alphabet Class C ($5.5M), and Microsoft ($2.6M).
• · The filing was signed by Christine Weiler, Chief Compliance Officer, on August 12, 2026.

12-08-2026

West Enclave Merger Corp. (WENC), a SPAC, reported net income of $509,855 for Q2 2026 and $469,457 for H1 2026, driven by interest income from its trust account. The company completed its IPO and private placement, raising gross proceeds of $116.15 million, and held $116.8 million in trust as of June 30, 2026. However, operating expenses exceeded operating income, resulting in a loss from operations of $141,596 for Q2 and $181,994 for H1.

• · Total assets increased from $454,470 at December 31, 2025 to $117,806,772 at June 30, 2026.
• · Total liabilities increased from $52,580 to $430,544 during the same period.
• · Ordinary shares subject to possible redemption: 11,500,000 shares at a redemption value of $10.16 per share as of June 30, 2026.
• · Accretion of ordinary shares to redemption amount was $6,605,334 during Q2 2026.
• · Net cash used in operating activities was $234,681 for H1 2026.
• · Net cash provided by financing activities was $117,264,320 for H1 2026.
• · The company had a promissory note – related party of $2,420 at December 31, 2025, which was repaid during H1 2026.
• · The company received $1,630 from issuance of EBC shares and $1,339 in advances from related party.

12-08-2026

WhiteFiber, Inc. reported total revenues of $28.8M for Q2 2026 (up 54.5% YoY from $18.7M) and $50.8M for H1 2026 (up 43.3% YoY from $35.4M), driven by strong growth in cloud services (+43.4% QoQ, +29.1% YoY for H1) and colocation services (+173.4% QoQ, +182.2% YoY for H1). However, the company's net loss widened significantly to $15.0M in Q2 2026 (vs. $8.8M in Q2 2025) and $27.0M in H1 2026 (vs. $7.4M in H1 2025), as operating expenses surged 37.0% QoQ and 67.0% YoY for H1, including a $5.0M impairment of capitalized software assets. Total assets grew 35.2% to $880.9M from $651.4M at year-end 2025, while total liabilities more than tripled to $543.5M (from $168.9M) due to new debt and convertible note issuance, and shareholders' equity declined 30.1% to $337.4M (from $482.5M). Cash and cash equivalents fell 51.0% to $56.1M from $114.4M at year-end 2025, despite $89.1M in operating cash flow, as heavy capital expenditures of $344.7M outpaced financing inflows.

• · The company issued $222.1M in convertible debt and $53.3M in third-party debt during H1 2026, while also purchasing a $120.0M zero-strike call option.
• · Capital expenditures on property, plant, and equipment totaled $344.7M in H1 2026, up from $131.0M in H1 2025.
• · Operating cash flow turned positive to $89.1M in H1 2026 from negative $6.8M in H1 2025, driven largely by a $63.6M increase in deferred revenue.
• · Accumulated deficit more than doubled to $51.6M from $24.5M at year-end 2025.
• · The company established several new subsidiaries in 2025-2026, including entities in Canada, Japan, Australia, Singapore, and the British Virgin Islands.
• · Weighted average diluted shares outstanding increased 43.0% to 38.7M in Q2 2026 from 27.0M in Q2 2025.
• · Loss per share (basic and diluted) worsened to $(0.39) in Q2 2026 from $(0.33) in Q2 2025, and to $(0.70) in H1 2026 from $(0.27) in H1 2025.

12-08-2026

Performance Food Group Company (PFGC) reported strong fourth-quarter and full-year fiscal 2026 results, with total case volume up 3.5% in Q4 and 5.1% for the full year. Net sales grew 6.4% to $18.0 billion in Q4 and 7.2% to $67.8 billion for the full year, while adjusted EBITDA rose 7.4% to $587.5 million in Q4 and 9.2% to $1,929.4 million for the full year. However, adjusted diluted EPS growth was modest at 2.6% in Q4 and 1.6% for the full year, and the Specialty segment's adjusted EBITDA declined 0.5% in Q4.

• · Q4 FY26 operating expenses rose 6.4% to $1.8 billion, driven by acquisitions, higher fuel costs, and personnel expenses.
• · Full-year FY26 operating expenses rose 9.1% to $7.2 billion, including legal and professional fees related to shareholder activism and a clean team agreement with US Foods.
• · The effective tax rate for Q4 FY26 was 26.8% vs. 25.6% in Q4 FY25; for FY26 it was 26.0% vs. 25.8% in FY25.
• · FY26 capital expenditures decreased 24.1% to $384.1 million from $506.0 million in FY25.
• · FY26 free cash flow increased 46.2% to $1,029.6 million from $704.1 million in FY25.
• · As of June 27, 2026, $498.5 million remained available under the $500 million share repurchase program.
• · Q4 FY26 Foodservice independent sales were 43.1% of total Foodservice sales.
• · Q4 FY26 Foodservice operating expenses impacting adjusted EBITDA increased 9.9% YoY.
• · Q4 FY26 Convenience gross profit contributing to adjusted EBITDA increased 6.2% YoY.
• · Q4 FY26 Specialty operating expenses impacting adjusted EBITDA increased 8.4% YoY, including a significant bad debt recovery in the prior year period.
• · FY27 guidance includes a 53rd week impact.
• · The company does not provide a reconciliation of forward-looking adjusted EBITDA to GAAP net income due to the unpredictability of certain items.

12-08-2026

Altimmune reported a net loss of $22.8 million for Q2 2026, slightly wider than the $22.1 million loss in Q2 2025, driven by increased R&D and G&A expenses. However, the company strengthened its cash position to $519 million following a $225 million public offering, and achieved key clinical milestones including the initiation of the Phase 3 PERFORMA trial in MASH and positive topline data from the Phase 2 RECLAIM trial in AUD. The company's momentum is balanced by rising operating costs and a still-negative bottom line.

• · The company completed an oversubscribed public offering in April 2026, raising $225 million in gross proceeds.
• · Pemvidutide received Breakthrough Therapy Designation from the FDA for MASH and Fast Track designation for AUD.
• · The PERFORMA Phase 3 MASH trial has a 52-week data readout anticipated in 2029.
• · Topline data from the RESTORE Phase 2 ALD trial is expected in the second half of 2027.
• · The company plans to relocate its corporate headquarters to Morristown, New Jersey later in 2026.
• · Total assets increased to $527.2 million as of June 30, 2026, up from $279.9 million at December 31, 2025.
• · Accumulated deficit grew to $694.9 million as of June 30, 2026.
• · Weighted-average shares outstanding increased significantly to 185.4 million in Q2 2026 from 81.5 million in Q2 2025, reflecting the April 2026 offering.

12-08-2026

Dyadic International reported Q2 2026 revenue of $961,138, a slight decrease of 0.6% YoY, while net loss widened 18.8% to $2,123,884 due to higher costs of revenue and G&A expenses. The company highlighted commercial progress in recombinant protein sales and partnerships, but cash position declined to $4.8 million from $8.6 million at year-end 2025, raising going-concern risks.

• · Revenue decline was driven by a $89,563 decrease in R&D revenue and absence of $250,000 milestone revenue, partially offset by a $334,071 increase in grant revenue.
• · Cost of grant revenue increased $395,709, while cost of R&D revenue decreased $25,135.
• · G&A increase was due to higher rebranding/business development ($322,638), legal/accounting ($115,836), and other expenses ($43,639), partially offset by lower share-based compensation ($196,408) and incentives ($32,472).
• · Net loss per share remained flat at $(0.06) YoY despite higher net loss due to increased share count.
• · Total liabilities exceeded total assets by $2,387,244 as of June 30, 2026.
• · The company has a going concern risk as noted in forward-looking statements.

12-08-2026

Capstone Holding Corp. (CAPS) filed a 10-Q/A restating its financials for the three and six months ended June 30, 2025, primarily to correct the weighted average share count used in EPS calculations. For Q2 2025, net sales were essentially flat at $12,852K vs $12,886K in Q2 2024, while gross profit improved 13.2% to $3,130K. However, the company swung to an operating loss of $260K from a $14K profit in the prior-year quarter, and the net loss attributable to stockholders widened to $700K from $1,328K (which included preferred unit charges). Cash used in operations more than tripled to $3,992K in H1 2025 from $1,135K in H1 2024, and total long-term debt increased to $5,827K from $6,323K at year-end 2024.

• · The 10-Q/A restatement reduced the weighted average share count for H1 2025 from 5,406,305 to 3,405,568, increasing the net loss per share from $0.58 to $0.92.
• · Total long-term debt increased to $9,607K at June 30, 2025 from $8,444K at December 31, 2024, driven by a $1,958K increase in the mezzanine term loan from Stream Finance.
• · The company had $773K in cash at June 30, 2025, up from $11K at the start of the year, primarily due to $5,032K in proceeds from IPO and stock issuances.
• · Selling, general and administrative expenses rose 23.3% to $3,390K in Q2 2025 from $2,750K in Q2 2024, contributing to the operating loss.
• · Interest expense increased to $440K in Q2 2025 from $394K in Q2 2024.
• · The company issued 1,250,000 shares in a public offering and 215,054 commitment shares under an equity line of credit during H1 2025.
• · The seller's note with Avelina Masonry, LLC is in default, with $222K of accrued interest unpaid at June 30, 2025.
• · The Special Preferred Membership Interests were exchanged for loans in March 2025, adding $1,143,646 in principal and a $695,000 amendment fee.

12-08-2026

Arbutus Biopharma reported a net loss of $5.1M for Q2 2026, swinging from net income of $2.5M in Q2 2025, as revenue dropped 91% to $1.0M due to the conclusion of a prior partnership. However, the company maintains a strong cash position of $92.6M and received a $178.4M initial payment from the Moderna settlement in July 2026, with plans to return up to $230M to shareholders via share repurchases. The company also advanced its imdusiran program with FDA Fast Track designation and alignment on a Phase 2b trial design, while filing three international patent lawsuits against Pfizer/BioNTech.

• · Net loss per share was $0.03 in Q2 2026 vs income of $0.01 in Q2 2025.
• · Operating cash used was $14.1M in H1 2026, improved from $29.1M in H1 2025.
• · R&D expenses fell 47% YoY due to workforce reduction and discontinuation of in-house scientific research.
• · G&A expenses rose 17% YoY due to higher stock compensation.
• · The company owns approximately 16% of Genevant's outstanding common equity and expects a material dividend from Genevant in Q3 2026.
• · Imdusiran has achieved functional cure in 10 chronic HBV patients to date, with 8 patients sustaining functional cure for over two years.
• · 41 additional patients were able to remain off NA therapy for at least 48 weeks in Phase 2a trials.
• · The company had no restructuring costs in Q2 2026 vs $0.2M in Q2 2025.

12-08-2026

Ming Shing Group Holdings Ltd (MSW) announced an agreement to acquire Meals Through Seasons Limited for $510 million, payable entirely in stock and convertible notes. The acquisition follows a non-binding MOU signed in July 2026 and targets the organic agricultural supply chain business. However, the consideration is based on unaudited financial forecasts and no independent valuation was obtained, and the deal will cause significant dilution to existing shareholders.

• · The MOU signed July 29, 2026, related to graphene thermal management in agriculture but has not generated any revenue.
• · Consideration shares of 150,000,000 Class A Ordinary Shares at $1.00 reference price will dilute existing shareholders significantly.
• · The $360M convertible notes have no interest, no fixed maturity, and conversion is contingent on performance milestones (net profit after tax thresholds) and capped at 24% voting rights per holder.
• · Conversion of notes is tranched over three financial years; failure to meet a threshold in one year is not curable by later performance.
• · Closing conditions include Nasdaq notification (Listing Rule 5250(e)(2)) without objection, and due diligence completion by the company.
• · The company did not obtain an independent valuation or fairness opinion for the target.
• · SPA can be terminated if closing does not occur by October 31, 2026.
• · The company is relying on Cayman Islands home country practice to bypass Nasdaq shareholder approval requirements for the transaction.

12-08-2026

Protalix BioTherapeutics reported strong Q2 2026 results with total revenue climbing to $53.6 million year-to-date from $25.8 million in the prior period, driven by Elfabrio® sales and a $25.0 million milestone payment from Chiesi. The company achieved year-to-date profitability with net income of $22.1 million, compared to a net loss of $3.5 million in the first half of 2025. However, revenues from license and R&D services declined to $0.1 million in Q2 2026 from $0.2 million in Q2 2025, and the company expects minimal such revenues going forward.

• · Elfabrio® U.S. patent term extended to November 17, 2035 via USPTO Patent Term Extension certificate issued May 4, 2026.
• · Elfabrio® received orphan drug designation and Marketing Authorization in South Korea in May 2026.
• · PRX-115 U.S. Patent No. 12,674,146 issued July 7, 2026, strengthening IP position.
• · Top-line results for PRX-115 Phase 2 RELEASE trial anticipated in second half of 2027.
• · Company has no outstanding debt or warrants.
• · Full-year 2026 Elfabrio® sales guidance (ex-milestones): $33.0M to $35.0M; Elelyso® sales guidance: $20.0M to $23.0M.
• · Q2 2026 net income per share: $0.05 basic and diluted; H1 2026 net income per share: $0.28 basic, $0.27 diluted.
• · Q2 2026 R&D expenses benefited from a $2.1 million grant receivable under new R&D law.
• · Taxes on income increased significantly due to GILTI limitations under IRC Section 174 and taxes on the $25 million milestone payment.

12-08-2026

PGGM Investments filed its Form 13F-HR for the quarter ended June 30, 2026, reporting a portfolio of 59 equity holdings with a total market value of approximately $4,064,583. The filing shows a diversified portfolio with top holdings in NVIDIA ($218,517), Alphabet ($194,407), Thermo Fisher Scientific ($175,344), Eli Lilly ($158,093), and Linde ($157,816). The portfolio is heavily weighted toward technology and healthcare sectors, with significant positions in real estate investment trusts (REITs) such as Sunrun ($127,738) and Digital Realty Trust ($24,022).

• · The filing was submitted on August 12, 2026, for the period ending June 30, 2026.
• · PGGM Investments reported sole voting and dispositive power over all 59 holdings.
• · The largest position by value is NVIDIA at $218,517 (1,092,096 shares), followed by Alphabet at $194,407 (543,993 shares).
• · The smallest position is Essential Properties Realty Trust at $328 (11,005 shares).
• · The portfolio includes a significant number of REITs: Sunrun, Digital Realty Trust, Welltower, CubeSmart, Equity Lifestyle Properties, Healthcare Realty Trust, Healthpeak Properties, Macerich, Prologis, Essential Properties Realty Trust, American Homes 4 Rent, Public Storage, Brixmor Property Group, Kilroy Realty, Simon Property Group, Ventas, Invitation Homes, Americold Realty Trust, Federal Realty Investment Trust, Host Hotels & Resorts, Alexandria Real Estate Equities, and Ryman Hospitality Properties.

12-08-2026

Applied Aerospace & Defense reported record Q2 FY26 revenue of $167.3M, up 47.4% YoY, driven by strong growth across all end markets, particularly C5ISR and Precision Strike Systems (+262%). However, the company incurred a net loss of $154.0M due to share-based compensation and IPO-related expenses, compared to a net loss of $4.7M in the prior year. Adjusted EBITDA rose 38.5% to a record $36.4M, and the company completed a $683.0M IPO, reducing pro forma net leverage to 2.7x.

• · Revenue growth in Defense Aviation and Airborne Systems was only 4.8% YoY, the slowest of the three segments.
• · Selling, general, and administrative expenses surged to $123.3M in Q2 FY26 from $11.6M in Q2 FY25, primarily due to IPO-related share-based compensation.
• · Operating income swung to a loss of $96.2M in Q2 FY26 from a profit of $13.9M in Q2 FY25.
• · Total debt (current + long-term) decreased to $400.5M as of June 30, 2026 from $634.0M at December 31, 2025, reflecting IPO proceeds used to pay down debt.
• · Accumulated deficit grew to $232.1M from $63.0M at year-end 2025.

12-08-2026

Milestone Pharmaceuticals reported Q2 2026 financial results and a corporate update. Revenue from its newly launched CARDAMYST product was $0.6 million in the quarter, but the net loss widened to $28.6 million from $13.0 million a year ago, driven by launch-related SG&A expenses. The company had $170.6 million in cash, providing a runway into H2 2027.

• · CARDAMYST launched mid-February 2026.
• · 25% of commercial lives covered at Q2 end, but increased to ~50% as of August 2026 due to formulary additions (e.g., UnitedHealthcare).
• · CARDAMYST nominated for Prix Galien USA Awards 'Best Pharmaceutical Product' 2026.
• · Phase 3 AFib-RVR trial (ReVeRA-301) sites activated; first patient enrollment expected H2 2026.
• · EMA decision for PSVT expected H1 2027.
• · NMPA (China) review ongoing; partner Everest Medicines responsible.
• · Two articles supporting CARDAMYST published in Journal of the American College of Cardiology: Advances.
• · Q2 2026 net loss $28.6M ($0.21/share) vs. $13.0M ($0.20/share) in Q2 2025.
• · Cash runway expected into H2 2027.

12-08-2026

Local Bounti reported Q2 2026 revenue of $13.9M, up 14% YoY (from $12.1M) and 4% sequentially, while net loss improved to -$19.8M from -$21.6M. Adjusted EBITDA loss narrowed 17% YoY to -$5.8M, but gross profit fell to $1.0M from $1.5M and adjusted gross margin slipped to 27% from 30%, primarily due to temporary packing inefficiencies at its Georgia facility. The company also received an additional $12.5M investment from an existing strategic investor subsequent to quarter-end.

• · General and administrative expenses decreased by $0.5M to $7.5M in Q2 2026 from $8.0M in Q2 2025.
• · Adjusted general and administrative expense decreased 17% to $4.1M from $5.0M year-over-year.
• · Net interest expense decreased by $0.1M in Q2 2026 vs prior year.
• · The company had $10.1M in cash and restricted cash at quarter end and received an additional $12.5M from a strategic investor post-quarter.
• · Fully diluted share count as of June 30, 2026 was approximately 42.5M shares.
• · Yield improvement initiatives at California facilities are expected to deliver up to 20% improvement to yields.
• · Seed costs have been lowered by approximately 20% year-over-year through more efficient seeding practices.
• · The company extended supply agreements with multiple national accounts through Q1 2027.

12-08-2026

AustralianSuper Pty Ltd filed its quarterly Form 13F-HR with the SEC for the period ending June 30, 2026, disclosing its U.S. equity holdings as of that date. The portfolio is heavily concentrated in mega-cap technology stocks, with Apple Inc. ($1.79B), Microsoft Corp. ($843M), and NVIDIA Corp. ($1.46B) representing the largest positions. The filing provides a snapshot of the fund's long equity exposures but does not include any period-over-period comparisons, so no performance trends can be assessed.

• · The filing reports 288 equity positions with a total reported market value of approximately $23.1 billion (sum of all disclosed values).
• · Top 10 holdings account for roughly 40% of the portfolio value.
• · The portfolio includes significant exposure to financials (Goldman Sachs, Morgan Stanley, MetLife, Principal Financial) and healthcare (Eli Lilly, Biogen, Gilead, HCA Healthcare, IDEXX).
• · Energy holdings include Exxon Mobil, Marathon Petroleum, Phillips 66, Devon Energy, and Diamondback Energy.
• · The fund holds positions in several Canadian companies: Canadian Imperial Bank of Commerce, Canadian Natural Resources, Canadian Pacific Kansas City, Barrick Gold, Agnico Eagle Mines, Kinross Gold, Manulife Financial, and Suncor Energy.
• · No period-over-period comparison data is available in this filing, so changes in positions or market values cannot be assessed.

12-08-2026

McGowan Group Asset Management, Inc. filed its Form 13F-HR for the quarter ended June 30, 2026, reporting 154 equity holdings with a total market value of approximately $823.1 million. The portfolio is heavily weighted toward fixed-income and income-oriented securities, with top positions in BlackRock Corporate Hi Yld FD Inc ($38.98M), AllianceBernstein Global High ($38.33M), Cohen & Steers Infrastructure ($38.37M), and Nuveen Global High Income FD ($47.77M). The filing also reveals significant holdings in energy infrastructure (Plains GP Hldgs $32.59M, Enterprise Prods Partners $13.63M, Energy Transfer $17.91M) and select large-cap technology stocks (Alphabet $11.01M, Apple $5.50M, Microsoft $1.26M).

• · The filing includes a small number of options positions: a put on Quanta Services Inc (300 shares) and a call on Enovix Corporation (7,000 shares).
• · The portfolio holds several closed-end funds (CEFs) focused on municipal bonds and high-yield income, indicating a strong income-oriented strategy.
• · Notable energy sector exposure includes holdings in Cheniere Energy Partners ($14.48M), EQT Corp ($11.08M), and Chevron ($6.84M).
• · Technology holdings include a mix of mega-caps (Apple $5.50M, Alphabet $11.01M, Microsoft $1.26M) and smaller positions in companies like SoundHound AI ($243K) and SolarEdge ($233K).
• · The portfolio also includes a position in Bed Bath & Beyond Inc ($62,966), a company that filed for bankruptcy in 2023, suggesting a distressed or speculative holding.

12-08-2026

CRCM LP filed its quarterly 13F-HR report for the period ending June 30, 2026, disclosing 12 equity holdings with a total market value of approximately $144.2 million. The portfolio is concentrated in small-cap and thematic names, with the largest positions in iShares Gold Trust ($98.3M), AI Financial Corp ($7.4M), and Atrium Therapeutics ($7.8M). The filing reflects a shift toward precious metals and digital assets, including a new position in iShares Bitcoin Trust ($10.1M), while maintaining exposure to speculative biotech and special-purpose acquisition companies.

• · The portfolio is heavily weighted toward iShares Gold Trust, which alone accounts for approximately 68% of total reported value.
• · New positions include iShares Bitcoin Trust (303,555 shares, $10.1M) and BitGo Holdings Inc (1,312,171 shares, $6.8M), indicating a thematic tilt toward digital assets.
• · The largest single holding by share count is AI Financial Corp with 12,701,530 shares, valued at $7.4M.
• · Smaller speculative positions include Playboy Inc (764,825 shares, $933K) and ProCap Acquisition Corp (160,656 shares, $1.7M), a SPAC.
• · No period-over-period comparisons are available as this is a single-quarter filing without prior-quarter data.

12-08-2026

BSN Capital Partners Ltd filed its Form 13F-HR for the quarter ended June 30, 2026, disclosing a portfolio of 37 equity holdings with a total reported market value of approximately $2.21 billion. The fund's largest positions include iShares Core S&P 500 ETF ($297.7M), Goldman Sachs Group ($162.5M in one block), Apple ($130.4M), and NVIDIA ($123.4M). The filing reflects a diversified portfolio with significant exposure to technology and financial sectors.

• · The filing includes holdings from two other related filers: BSN Holdings Ltd and BSN Capital LLP.
• · The fund holds multiple blocks of the same securities (e.g., three separate Goldman Sachs positions, three NVIDIA positions, two Alphabet Class C positions, two Apple positions, two Broadcom positions, and three Select Sector SPDR Financial ETF positions).
• · The largest single position by value is the iShares Core S&P 500 ETF at $297.7M, followed by Goldman Sachs at $162.5M.
• · The fund has significant exposure to Indian equities via ICICI Bank ADR ($87.7M) and Brazilian equities via Vale ADR ($69.7M).
• · The filing was signed by Jeremy Steven Nye, Director, on August 12, 2026.

12-08-2026

SAXON INTERESTS, INC. filed its quarterly Form 13F-HR for the period ending June 30, 2026, disclosing a diversified equity and ETF portfolio valued at approximately $362 million. The filing shows significant holdings in major tech and growth names such as Apple ($12.7M), Amazon ($8.1M), Microsoft ($6.6M), and NVIDIA ($8.7M), alongside large positions in iShares and Invesco ETFs. The report reflects a broad, multi-manager investment strategy with both direct equity and ETF exposures across U.S. and international markets.

• · The filing was signed by Jaclyn Gilbert, Chief Compliance Officer, on August 12, 2026.
• · The portfolio includes 238 distinct securities with a total market value of $362,006,745.
• · The largest single holding by value is the Invesco Exchange Traded FD T RAFI US 1000 ETF at $31,086,868 (575,363 shares).
• · Other top ETF holdings include iShares TR MSCI US GARP ETF ($16,061,621), American Centy ETF TR Avantis Emgmkt ($12,540,712), and American Centy ETF TR US Sml Cp Valu ($11,453,774).
• · Among individual stocks, the largest positions are Apple Inc. ($12,738,462), Amazon.com Inc. ($8,131,109), NVIDIA Corporation ($8,666,715), Microsoft Corp. ($6,597,081), and JPMorgan Chase & Co. ($5,071,884).
• · The portfolio includes a small position in New Horizon Aircraft Ltd ($98,500, 50,000 shares) and Opendoor Technologies Inc ($58,674, 12,700 shares).
• · The filing does not include any period-over-period comparisons, so no growth or decline metrics are available.

12-08-2026

Boston Family Office LLC filed its Form 13F-HR for the quarter ended June 30, 2026, reporting 315 equity holdings with a total market value of approximately $1.65 billion. The portfolio is heavily weighted toward large-cap technology and healthcare names, with top holdings including Apple Inc. ($82.3M), Alphabet Inc. Class C ($59.1M), Amazon.com ($56.3M), Microsoft ($53.7M), and Palo Alto Networks ($46.1M). The filing reflects a diversified, growth-oriented strategy with significant exposure to mega-cap tech, while also including meaningful positions in fixed-income ETFs and iBonds Treasury ladders.

• · The filing was signed by George Beal, Managing Partner, on August 12, 2026.
• · The portfolio includes a significant allocation to fixed-income ETFs, particularly iShares iBonds Treasury ladders spanning 2026-2033, with the largest positions in the 2028 and 2027 series ($6.4M and $6.3M respectively).
• · Other notable positions include Invesco Variable Rate Preferred ETF ($6.5M), iShares Core S&P Small Cap ETF ($7.5M), and iShares Core S&P Mid-Cap ETF ($4.1M).
• · The portfolio holds a mix of individual equities and ETFs, with a tilt toward growth and technology sectors.

12-08-2026

Ponta Wealth Partners, LLC filed its Form 13F-HR for the quarter ended June 30, 2026, disclosing 199 equity holdings with a total market value of approximately $186.9 million. The portfolio is heavily weighted toward large-cap technology stocks, with top holdings including Apple Inc. ($12.8M), NVIDIA Corporation ($13.4M), and Microsoft Corporation ($6.8M). The filing reflects a diversified strategy across sectors, with significant positions in Dimensional ETFs and Innovator ETFs, but no period-over-period comparison data is available in this initial filing.

• · Top 10 holdings by market value: NVIDIA ($13.4M), Apple ($12.8M), Microsoft ($6.8M), Alphabet Cl C ($7.0M), Alphabet Cl A ($4.6M), Amazon ($5.5M), JPMorgan Chase ($3.8M), Broadcom ($3.2M), Advanced Micro Devices ($2.8M), Visa ($2.8M).
• · Largest ETF positions: Dimensional ETF Trust Intl Core Equity ($6.4M), Dimensional ETF Trust US Larg Valu ETF ($4.0M), Dimensional ETF Trust US Targeted Vlu ($2.9M), Dimensional ETF Trust World Ex US Core ($2.9M).
• · Significant Innovator ETF holdings: US Eqty Pwr Buf (45782C318) $1.3M, US EQT PWR BUF (45782C870) $691K, US EQTY PWR BUF (45782C748) $614K.
• · Notable small-cap positions: Vestis Corporation (20,442 shares), Waystar Hldg Corp (23,967 shares), Columbia Bkg Sys Inc (6,488 shares).
• · All holdings are listed with sole voting and dispositive power; no shared or non-voting positions reported.

12-08-2026

ENERGY RESOURCES 12, L.P. reported a net loss of $924,036 for the six months ended June 30, 2026, a significant improvement from a net loss of $3,435,946 in the prior-year period. Total revenue decreased 7.4% to $13,224,797, driven by lower oil and NGL revenue, though natural gas revenue increased. The partnership swung to a net income of $457,056 in Q2 2026 from a net loss of $2,345,352 in Q2 2025, aided by a $406,472 gain on derivatives and lower depreciation charges.

• · The partnership had a derivative asset of $485,212 as of June 30, 2026, compared to zero at December 31, 2025, and recognized a $406,472 gain on derivatives in Q2 2026.
• · Cash from operations declined 30.7% to $3,880,838 for the six-month period, while capital expenditures more than tripled to $3,745,190.
• · The revolving credit facility was reclassified from non-current ($5.8M at Dec 31, 2025) to current liability ($5.8M at June 30, 2026).
• · No distributions were paid to limited partners in the first half of 2026, compared to $7,072,146 paid in the first half of 2025.
• · Depreciation, depletion, amortization and accretion decreased 33.2% to $5,425,575 for the six-month period.

12-08-2026

Federal Home Loan Bank of Dallas reported net income of $123.5M for Q2 2026 and $245.4M for H1 2026, down 17.1% and 18.1% respectively from the same periods in 2025, driven by lower net interest income and trading losses. Total assets decreased slightly to $107.8B from $108.5B at year-end 2025, while total capital increased to $6.8B. The bank experienced a sharp decline in interest income from advances and bonds, partially offset by higher income from resale agreements and trading securities.

• · Total other income fell to $9.1M in Q2 2026 from $13.8M in Q2 2025, a decline of 34.2%, driven by net losses on trading securities of $5.1M vs. gains of $3.7M.
• · Total other expense decreased slightly to $41.1M in Q2 2026 from $42.3M in Q2 2025, a decline of 2.9%.
• · Provision for credit losses dropped to $0.8M in Q2 2026 from $1.6M in Q2 2025, a decline of 48.5%.
• · Total comprehensive income was $184.8M in Q2 2026 vs. $85.0M in Q2 2025, more than doubling due to positive other comprehensive income.
• · Cash and due from banks plummeted 80.4% from $39.4M at Dec 31, 2025 to $7.7M at Jun 30, 2026.
• · Interest-bearing deposits increased 28.8% to $3.5B from $2.7B at year-end 2025.
• · Trading securities nearly doubled, rising 78.3% to $6.3B from $3.5B at Dec 31, 2025.
• · Available-for-sale securities decreased 8.1% to $17.8B from $19.3B.
• · Held-to-maturity securities declined 12.1% to $922.0M from $1.0B.
• · Mortgage loans held for portfolio increased 5.4% to $6.9B from $6.6B.
• · Deposits grew 25.8% to $2.8B from $2.2B.
• · Mandatorily redeemable capital stock surged to $85.2M from $8.0M, a 970% increase.
• · Accrued interest payable rose 20.3% to $428.5M from $356.4M.
• · Other liabilities increased 73.7% to $1.5B from $884.6M.
• · Net cash provided by operating activities was $289.7M in H1 2026 vs. net cash used of $181.4M in H1 2025.
• · Net cash provided by investing activities was $1.2B in H1 2026 vs. $12.5B in H1 2025, a 90.3% decline.
• · Net cash used in financing activities was $1.5B in H1 2026 vs. $12.3B in H1 2025.
• · Weighted average interest rate on advances decreased to 3.75% at Jun 30, 2026 from 3.83% at Dec 31, 2025.

12-08-2026

Universal Token, Inc. reported a net loss of $18,636 for Q2 2026 (three months ended June 30, 2026), a significant improvement from the $221,591 net loss in the same quarter of 2025. For the first half of 2026, the net loss was $36,361 versus $315,552 in H1 2025. However, the company still has zero revenue, and its cash position has deteriorated sharply from $1,842 at the start of the period to just $27 at June 30, 2026, while it took on $44,000 in related-party loans and $5,264 in related-party advances to fund operations.

• · Zero revenue for both Q2 and H1 periods in 2026 and 2025.
• · Operating expenses fell sharply: Q2 2026 total operating expenses were $18,636 vs $221,426 in Q2 2025; H1 2026 was $36,361 vs $314,579 in H1 2025.
• · Accounts payable and accrued expenses decreased from $30,000 at Dec 31, 2025 to $16,864 at June 30, 2026.
• · No cash was raised from stock issuance in H1 2026, compared to $935,000 in H1 2025.
• · Non-cash financing: common stock issued for related party debt was $0 in H1 2026 vs $487,500 in H1 2025.
• · Basic and diluted loss per share was $0.00 for all periods presented.
• · Accumulated deficit grew from $535,219 to $571,580 during H1 2026.
• · Total stockholders' equity decreased from $1,121,229 to $1,084,868.

12-08-2026

Angel Oak Capital Advisors, LLC filed its quarterly 13F-HR for the period ending June 30, 2026, reporting a portfolio of 30 equity holdings with a total market value of approximately $792.7 million. The filing shows a concentrated strategy in financials and fixed-income ETFs, with top positions including AGNC Investment Corp., Invesco Senior Loan ETF, and the firm's own Angel Oak Funds Trust products. No period-over-period comparisons are available in this filing, so performance trends cannot be assessed.

• · The filing is a 13F combination report filed by Angel Oak Capital Advisors, LLC with Empowered Funds, LLC as the reporting manager.
• · The largest single holding by value is AGNC Investment Corp. at $33,245,000 (305,000 shares).
• · The second largest holding is the Angel Oak High Yield Opportunities Fund at $65,038,945 (5,909,730 shares).
• · The portfolio includes a significant position in Patriot National Bancorp Inc. with 2,662,136 shares valued at $25,489,952.
• · Other notable holdings include Citigroup Inc. (600,000 shares, $39,760,000) and PennyMac Mortgage Investment Trust (8,118,200 shares, $9,157,338).
• · The filing includes multiple Angel Oak Funds Trust proprietary ETFs, indicating the firm invests in its own funds.

12-08-2026

The filing is a Schedule 13G/A submitted by The Vanguard Group, reporting a 10.2% passive beneficial ownership stake in H&R Block Inc. as of December 31, 2025. Vanguard holds 14,200,000 shares, an increase from 13,500,000 shares (9.8%) in the prior period, indicating gradual accumulation. However, the filing provides no information on company financials, management changes, or market events, limiting actionable insights.

• · Vanguard's ownership increased from approximately 9.8% to 10.2% of total shares outstanding.
• · The filing is an amendment (13G/A), indicating a change in ownership from the prior filing.
• · No other institutional investors, group filings, or activist intentions are disclosed.
• · The filing does not include any financial metrics, guidance, or operational data for H&R Block.

12-08-2026

Marathon Trading Investment Management LLC filed its Q2 2026 13F-HR with the SEC, reporting a total portfolio value of approximately $3.23 billion as of June 30, 2026. The fund holds concentrated positions in mega-cap tech (Alphabet, Meta, Amazon, Microsoft) alongside significant options exposure in Bitcoin and Silver ETFs, and speculative names like Beyond Meat and AMC Entertainment. The filing shows a mix of large common stock positions and substantial put and call options, indicating an active hedging and directional trading strategy.

• · The fund holds a significant number of put options on major indices and stocks, including $64.3M in Alphabet puts, $67.6M in Meta puts, and $46.3M in iShares Bitcoin Trust puts, suggesting a hedging or bearish tilt on these names.
• · Large call option positions in iShares Silver Trust ($179.3M OTR calls, $177.7M SOLE calls) indicate a strong bullish bet on silver.
• · Speculative positions include Beyond Meat (192,777 shares OTR, plus 2,135,800 call options OTR) and AMC Entertainment (145,991 shares OTR).
• · The fund also holds shares in distressed or bankrupt companies such as Bed Bath & Beyond (16,400 shares total) and Hertz Global Holdings (10,300 shares).
• · No prior period comparison data is available in this filing, so period-over-period changes cannot be calculated.

12-08-2026

Voya Financial Advisors, Inc. filed its quarterly Form 13F-HR for the period ending June 30, 2026, disclosing its U.S. equity and ETF holdings as of that date. The filing includes a large portfolio with major positions predominantly in fixed-income and balanced ETFs, such as the Vanguard Total Bond Market ETF ($181.8 M), Vanguard Intl Equity Index All World ex US ETF ($138.8 M), and iShares USD Investment Grade Corporate Bond ETF ($42.6 M), alongside sizable stakes in large-cap growth and value ETFs and individual equities like Apple, Microsoft, Amazon, and Nvidia.

• · The filing reported the largest individual equity position by value was Apple Inc. at $7,292,331 (10,498 shares), followed by Microsoft Corp. at $6,635,513 (18,004 shares), Amazon.com Inc. at $6,243,952 (26,001 shares), and Alphabet Inc. Class C at $5,712,561 (16,153 shares).
• · The top three ETF holdings by value were: Vanguard Total Bond Market ETF ($181.8M), Vanguard All-World ex-US ETF ($138.8M), and iShares USD Investment Grade Corporate Bond ETF ($42.6M).
• · The filing did not include any period-over-period comparisons; it is a snapshot of holdings as of June 30, 2026 only.

12-08-2026

Condor Capital Management filed its 13F-HR for the quarter ended June 30, 2026, reporting a portfolio value of approximately $1.33 billion across 173 holdings. The largest positions include Vanguard S&P 500 ETF ($159.5M), Vanguard Growth ETF ($70.7M), iShares Core MSCI EAFE ($68.3M), and VanEck Semiconductor ETF ($36.4M). The portfolio is heavily weighted toward equity ETFs and fixed-income ETFs, with notable holdings in mega-cap tech stocks like Apple ($35.3M), Microsoft ($18.9M), and Alphabet Class A ($24.0M).

• · Portfolio value of $1.33 billion as of June 30, 2026.
• · Top 10 holdings account for approximately $470 million, or about 35% of total portfolio value.
• · Largest sector exposures appear to be U.S. large-cap equities (via Vanguard S&P 500 ETF, iShares Core S&P 500 ETF, etc.) and international developed equities (iShares Core MSCI EAFE).
• · Significant fixed-income exposure through ETFs like iShares Short National Muni ETF ($8.4M), PIMCO 0-5 High Yield ETF ($16.7M), and PIMCO Short-Term Municipal Bond ETF ($13.6M).
• · Notable holdings in business development companies (BDCs) such as Ares Capital ($4.0M), Golub Capital BDC ($5.4M), and SLR Investment Corp ($5.7M).
• · Small positions in several SPACs and rights (e.g., AmperCap Acquisition, Galata Acquisition Corp II, Kensington Capital Acquisition) suggesting opportunistic or arbitrage strategies.
• · Crypto exposure via Fidelity Wise Origin Bitcoin ETF ($0.8M) and Grayscale Bitcoin Mini Trust ($0.6M) and Grayscale Ethereum Staking ($0.3M).
• · Largest single stock holding is Apple Inc. at $35.3 million (121,987 shares).

12-08-2026

Resolute Wealth Strategies, LLC filed its 13F-HR for the quarter ended June 30, 2026, reporting total holdings of approximately $258.3 million across 132 positions. The portfolio is heavily weighted toward large-cap U.S. equities and ETFs, with top holdings including Apple ($36.8M), JPMorgan Active Growth ETF ($16.4M), and Caterpillar ($13.1M). The filing shows a diversified mix of growth and value ETFs, along with select commodity and sector-specific exposures.

• · The filing was made on August 12, 2026, for the period ended June 30, 2026.
• · All 132 positions are held with sole voting and dispositive power.
• · The largest single position is Apple Inc. at $36.8M (127,167 shares), representing about 14.2% of the portfolio.
• · The portfolio includes a mix of 10 individual stocks and 122 ETFs/ETPs.
• · Notable smaller positions include Reddit Inc. ($1.95M), Palantir Technologies ($1.08M), and Robinhood Markets ($321,698).
• · The filing includes a position in Space Exploration Technologies Corp. (SpaceX) Class A common stock valued at $459,443.
• · Commodity exposures include SPDR Gold Shares ($6.16M), iShares Silver Trust ($832,795), and Agnico Eagle Mines ($321,880).
• · The portfolio has a significant allocation to fixed income via Fidelity Total Bond ETF ($11.9M), PIMCO Enhanced Short Maturity ETF ($10.8M), and JPMorgan Active Bond ETF ($520,181).

12-08-2026

Farringdon Capital, Ltd. disclosed its Q2 2026 equity portfolio in a 13F-HR filing, reporting holdings valued at approximately $201.8 million across 184 positions as of June 30, 2026. The filing shows significant exposure to Bitcoin and Ethereum ETFs, with iShares Bitcoin Trust ($11.6M) as the largest single holding, alongside major positions in Barclays ADR, Lloyds Banking Group ADR, NatWest Group ADR, and iShares 0-1 Year Treasury Bond ETF. The portfolio is concentrated in financials, digital assets, and energy, with no explicit period-over-period comparisons available.

• · The filing was signed by Yiyi Wang, Chief Investment Officer of Farringdon Capital, Ltd.
• · The fund holds 13 exchange-traded products dedicated to Bitcoin and Ethereum across six issuers, with a combined market value exceeding $40 million.
• · Large UK bank ADRs (Barclays, Lloyds, NatWest) collectively represent over $26.5 million in value.
• · The fund holds a long position in ProShares Short S&P 500 ETF ($400,301) and ProShares Short 20+ Year Treasury ETF ($401,394), indicating hedging or bearish views on U.S. equities and long-duration bonds.
• · Notable non-ETF top holdings include Lloyds Banking Group ADR ($10.5M), NatWest Group ADR ($9.2M), and Barclays ADR ($6.7M)
• · Holdings include 19 fixed-income ETF positions primarily in the iShares 0-1 Year Treasury Bond ETF ($10.5M).
• · The fund holds 9 cryptocurrency-related equity positions: Coinbase ($2.8M), Strategy Inc ($2.9M), and Wise Group PLC ($928K).

12-08-2026

Varma Mutual Pension Insurance Co filed its quarterly 13F-HR for the period ending June 30, 2026, disclosing 313 equity holdings with a total market value of approximately $18.87 billion. The portfolio is heavily concentrated in U.S. large-cap technology and financial stocks, with top holdings including Apple Inc. ($719M), Alphabet Inc. Class A ($561M), Microsoft Corp. ($426M), and Amazon.com Inc. ($410M). The filing reflects a diversified institutional portfolio with significant exposure to ETFs, including the Invesco MSCI North America ETF ($2.53B) and the iShares Expanded Tech Sector ETF ($1.38B).

• · The filing was signed by Chief Risk Officer Kaj Blomster on August 12, 2026.
• · All 313 holdings are listed with sole voting and dispositive power, indicating no shared or no authority positions.
• · The portfolio includes significant exposure to energy (Exxon Mobil $91.2M, Chevron $51.3M), healthcare (Eli Lilly $139M, Johnson & Johnson $98.2M, Merck $51.3M), and financials (JPMorgan $151M, Bank of America $68.9M, Goldman Sachs $56M).
• · Notable smaller positions include Coinbase Global ($599K), Fidelity National Information Services ($474K), and Fiserv ($647K).
• · The filing does not include any period-over-period comparisons, as 13F-HR filings are point-in-time snapshots without prior period data.

12-08-2026

WealthShield Partners, LLC filed its final 13F-HR for the period ended June 30, 2026, reporting total holdings of approximately $653.8 million. The filing notes that due to the acquisition of the firm, the reporting manager no longer has investment discretion and no future 13F filings will be submitted. The portfolio is heavily weighted toward iShares ETFs and large-cap tech stocks, with top holdings including iShares Core S&P 500 ETF ($53.5M), Amazon ($9.7M), and Alphabet Class A ($9.0M).

• · Firm was acquired, resulting in loss of investment discretion and cessation of 13F filings.
• · Portfolio includes 379 distinct holdings with total value of $653.8M.
• · Top equity holdings by value: iShares Core S&P 500 ETF ($53.5M), iShares S&P 500 Growth ETF ($17.7M), iShares S&P 500 Value ETF ($12.4M), Apple ($12.3M), Amazon ($9.7M), Alphabet Class A ($9.0M).
• · Significant positions in Innovator ETFs (defined-outcome buffer ETFs) across multiple series and expiration months.
• · Holdings include cryptocurrency-related ETFs: iShares Bitcoin Trust ($619K) and iShares Ethereum Trust ($130K).
• · No period-over-period comparison data available as this is a single-period filing.

12-08-2026

Oppenheimer & Close, LLC filed its Form 13F-HR for the quarter ended June 30, 2026, reporting 57 equity holdings with a total market value of approximately $158.5 million. The portfolio is heavily concentrated in small-cap financials (banks and thrifts), gold and precious metals miners, and select value/industrial names, with top positions including BRT Apartments, Seacor Marine Holdings, Hurco, and Taylor Devices. The filing reflects a long-only, value-oriented strategy with no put or call options reported.

• · The filing notes that certain holdings reported as 'Sole' are managed by Oppvest, LLC, which is managed by the same individuals as Oppenheimer & Close, LLC and is considered part of the registered investment adviser.
• · The largest position by market value appears to be Hurco Co (approx. $10.5M), followed by Seacor Marine Holdings (approx. $10.6M) and BRT Apartments (approx. $6.2M).
• · The portfolio includes a significant number of community and regional bank stocks (e.g., Ameriserv Financial, Blue Ridge Bankshares, CNB Financial, Peapack-Gladstone, etc.), indicating a strong value/small-cap tilt.
• · Gold and precious metals exposure is notable: Agnico Eagle, Alamos Gold, Barrick, Coeur Mining, Hecla Mining, Newmont, plus gold ETFs (SPDR Gold Trust, VanEck Junior Gold Miners, Sprott Physical Gold).
• · No put or call options were reported; all positions are common stock or ETF shares.
• · The filing is for the quarter ended June 30, 2026, filed on August 12, 2026.

12-08-2026

Pacific Ridge Capital Partners, LLC filed its Q2 2026 13F-HR with the SEC, disclosing 134 equity holdings with an aggregate market value of approximately $551.0 million as of June 30, 2026. The portfolio shows a strong tilt toward small-cap and micro-cap value positions, with the largest single positions being DHI Group (3.2M shares, $12.0M), Northeast Bank ($15.8M), and Red Robin Gourmet Burgers (1.8M shares, $14.2M). However, the portfolio includes several positions in companies with declining fundamentals, such as DMC Global (-33% YoY revenue decline) and Cooper Standard Holdings (negative EBITDA), indicating a high-risk, deep-value approach.

• · The filing reports SOLE voting authority for all shares; no shared or non-voting authority is indicated.
• · Largest number of shares held: DHI Group (3,228,701 shares), followed by Repay Holdings Cls A (2,240,738 shares) and Red Robin Gourmet Burgers (1,779,173 shares).
• · Smallest positions: PC Connection (9,716 shares), NPC/Standard Motor (14,631 shares), and Pathward Financial (19,516 shares).
• · No options, warrants, or convertible securities are reported in this filing.
• · The portfolio is heavily concentrated in financial services (banks, insurance), industrial services, and technology/software companies, with notable holdings in distressed or turnaround situations (e.g., Cooper Standard, DMC Global).

12-08-2026

Militia Capital Management LLC filed its 13F-HR for the quarter ended June 30, 2026, reporting a total portfolio value of approximately $3.37 billion across 278 holdings. The fund's top positions include Amazon.com Inc ($16.0M), EA Series Trust Mili Long Short ETF ($14.7M), Energy Transfer L.P. ($11.5M), and Axos Financial Inc ($9.7M). The filing reveals a highly diversified portfolio spanning technology, healthcare, energy, and financials, with notable new or increased positions in companies like Snap Inc (700,000 shares) and Inter & Co Inc (900,000 shares).

• · The fund holds a significant position in 3D Systems Corp (825,546 shares), a 3D printing company.
• · Hyperliquid Strategies Inc is a major holding with 727,387 shares.
• · The portfolio includes a mix of large-cap tech (NVIDIA, TSMC, Amazon, Alphabet) and smaller, more speculative names (Bitmine Immersion Tech, Nouveau Monde Graphite).
• · Exposure to the cannabis sector via Advisorshares Pure US Cannabis ETF (74,800 shares).
• · Significant holdings in energy infrastructure (Energy Transfer L.P., MPLX LP, Kinder Morgan).
• · The fund holds a position in its own proprietary ETF, the EA Series Trust Mili Long Short ETF (404,411 shares).

12-08-2026

NewEdge Advisors, LLC filed its quarterly 13F-HR report with the SEC for the period ending June 30, 2026, disclosing 4,200 positions with a total market value of approximately $33.57 billion. The filing shows a diversified portfolio across equities, ETFs, and closed-end funds, with top holdings including Alphabet Inc. (Class A and C combined ~$738M), Amazon.com Inc. (~$517M), and Advanced Micro Devices Inc. (~$294M). The report reflects the firm's investment strategy as of mid-2026, with significant allocations to technology, healthcare, and income-focused ETFs.

• · The filing includes a mix of common stocks, ETFs, and closed-end funds across various sectors.
• · Notable holdings include Alphabet Inc. Class A ($466.6M) and Class C ($271.8M), Amazon.com Inc. ($516.9M), and Advanced Micro Devices Inc. ($294.1M).
• · The portfolio also contains significant positions in income-oriented ETFs such as AB Active ETFs Inc. Short Duration Yield ETF ($34.2M) and Alps ETF Trust Alerian MLP ($32.6M).
• · Some positions show zero shares held (e.g., Acacia Research, Agora Inc., Acurx Pharmaceuticals), indicating possible complete exits or corrections.

12-08-2026

Agave Capital Management Ltd filed its 13F-HR for the quarter ended June 30, 2026, disclosing a portfolio of 12 equity holdings with a total market value of approximately $914.8 million. The largest positions include iShares Core S&P 500 ETF ($298.1M), NVIDIA Corporation ($221.9M), and IREN Limited ($79.8M). The filing reflects a concentrated, tech-heavy portfolio with significant exposure to semiconductors, cloud infrastructure, and broad market ETFs.

• · The filing is a 13F-HR for the quarter ended June 30, 2026, filed on August 12, 2026.
• · All 12 positions are held with sole voting and dispositive power; no shared or non-dispositive holdings.
• · The portfolio is heavily weighted toward technology and semiconductor stocks (NVIDIA, Microsoft, Broadcom, Alphabet, Amazon, Meta) and broad market ETFs.
• · IREN Limited (a bitcoin mining and data center company) is the third-largest position by value, indicating a thematic bet on crypto infrastructure.
• · The fund also holds sector-specific ETFs: utilities (Select Sector SPDR UTIL), banks (SPDR BANK), and regional banks (SPDR REGBNK), suggesting some diversification into financials and utilities.
• · No prior quarter comparison data is available in this filing, so period-over-period changes cannot be assessed.

12-08-2026

CSB Financial Inc. reported net income of $169,154 for Q2 2026 (vs. $161,982 in Q2 2025) and $255,885 for H1 2026 (vs. $219,112 in H1 2025), driven by higher net interest income and lower provision expenses. However, noninterest income declined 20.5% YoY in Q2 and 11.1% in H1 due to the absence of gains on loan sales, while noninterest expenses rose 7.1% YoY in Q2 and 14.2% in H1, partly due to higher salaries and occupancy costs.

• · Loans receivable decreased 0.7% from Dec 31, 2025 to June 30, 2026 ($92,991,369 to $92,308,006), while deposits grew 14.9%.
• · The company recorded zero provision for credit losses in both Q2 2026 and H1 2026, compared to $12,940 in the prior year periods.
• · Cash and cash equivalents surged to $15,776,837 as of June 30, 2026 from $6,428,668 at Dec 31, 2025, reflecting strong deposit inflows.
• · Gain on sale of loans was zero in Q2 and H1 2026, versus $5,033 in Q2 and H1 2025.
• · Salaries and employee benefits increased 9.4% YoY in Q2 2026 ($467,897 vs $427,664) and 20.1% in H1 2026 ($1,005,561 vs $837,346).
• · Occupancy and equipment expense rose 41.7% YoY in Q2 2026 ($42,146 vs $29,753).
• · Other comprehensive loss was $2,134 in Q2 2026 vs income of $5,657 in Q2 2025.
• · Total liabilities increased to $103,599,184 at June 30, 2026 from $94,408,463 at Dec 31, 2025.

12-08-2026

Wittenberg Investment Management, Inc. filed its Form 13F-HR for the quarter ended June 30, 2026, reporting $292.5 million in total disclosed equity holdings across 78 positions. Major top holdings include Alphabet Inc. (Class A and C combined ~$50.6M), Berkshire Hathaway (~$50.8M), SiriusXM Holdings (~$27.6M), Apple Inc. (~$28.9M), and Warner Bros Discovery (~$14.4M). The portfolio is concentrated in media, technology, and financial sectors with notable exposure to Liberty Media affiliates and smaller positions in energy and REITs.

• · Filing reports 78 positions totaling $292.5 million in market value as of June 30, 2026.
• · No period-over-period comparison data is provided in a 13F initial filing (this is the initial filing for the quarter).
• · All listed shares are held with sole voting and dispositive power except as noted (e.g., small shared/other amounts on some positions).
• · Significant positions include Liberty Broadband Corp. (Series A: 259,624 shares; Series C: 34,906 shares), E.W. Scripps Co. (2,636,071 shares), and Thryv Holdings (1,111,415 shares).
• · Long-tail holdings: smallest market values include Avalon Holdings ($91,592), Yext ($151,775), and Franklin Street Properties ($171,337).

12-08-2026

Measured Risk Portfolios, Inc. filed its quarterly 13F-HR for the period ending June 30, 2026, reporting total holdings of approximately $112.4 million across 65 equity and ETF positions. The portfolio is diversified with top holdings including MRP Synthequity (a proprietary ETF), Apple Inc., Sprouts Farmers Market, and BondBloxx ETFs, reflecting a mix of growth, income, and fixed-income strategies. The filing shows a balanced approach with significant exposure to both equities and fixed-income instruments, but no prior-period comparison is available to assess performance trends.

• · The portfolio includes 65 positions with a total market value of $112,415,068.
• · The largest holding is MRP Synthequity (a proprietary ETF) valued at $22,856,925, representing about 20% of the portfolio.
• · The portfolio holds multiple call options on the SPDR S&P 500 ETF (ticker SPY) with notional exposure of 708,400 shares across three tranches.
• · Fixed-income exposure includes BondBloxx Treasury ETFs, iShares Floating Rate Bond ETF, and Goldman Sachs Access Treasury ETF.
• · Sector ETFs include consumer staples, technology, health care, energy, and utilities via Select Sector SPDRs.
• · International exposure is limited to iShares MSCI EAFE ETF ($720,823) and some multinational holdings.
• · No prior-period comparison is available in this filing, so performance trends cannot be assessed.

12-08-2026

Utah Medical Products (UTMD) reported a decline in financial performance for Q2 and H1 2026. Net sales for Q2 2026 fell 14.3% YoY to $8.529M, and net income decreased 11.9% to $2.686M. While the company maintains a strong balance sheet with $87.528M in cash and investments and no debt, the top-line and bottom-line declines reflect ongoing operational headwinds.

• · Gross profit margin remained relatively stable at 55.8% in Q2 2026 vs 56.2% in Q2 2025.
• · Operating income margin was 31.1% in Q2 2026 vs 32.1% in Q2 2025.
• · Litigation fees increased to $498K in Q2 2026 from $284K in Q2 2025.
• · Amortization expense decreased sharply to $16K in Q2 2026 from $540K in Q2 2025.
• · Cash provided by operating activities fell to $4.492M in H1 2026 from $7.337M in H1 2025, a decline of 38.8%.
• · The company reduced share buybacks significantly: $0.206M in H1 2026 vs $6.708M in H1 2025.
• · Dividends paid remained consistent at $1.976M in H1 2026 vs $2.018M in H1 2025.
• · Foreign currency translation had a negative impact of $536K in H1 2026 vs a positive $2.546M in H1 2025.
• · Total liabilities decreased to $2.539M as of June 30, 2026 from $3.274M as of December 31, 2025.
• · The company has no long-term debt.

12-08-2026

Onconetix, Inc. filed an S-1 registration statement summarizing its shift from commercial-stage biotech to a pre-revenue oncology diagnostics company, having abandoned its only FDA-approved product (ENTADFI) and relying on the commercial launch of its Proclarix prostate cancer test. The company reported a cash balance of $5.4 million as of August 10, 2026, an accumulated deficit of $135.4 million, and a quarterly operating cash burn of $2.1 million, stating its cash is not sufficient to fund operations for one year. While Proclarix is now offered in the UK through a screening initiative (approximately 100 tests as of March 31, 2026) and a multi-center U.S. study has begun, the company faces a going-concern risk and has no sustained revenue stream.

• · ENTADFI was fully impaired as of June 30, 2024, and inventory was destroyed; three employees were terminated effective April 30, 2024.
• · Proclarix is CE-marked and for sale in Europe; the PRIME study with LabCorp has enrolled first participants and targets up to 500 men.
• · The company has no approved products for sale aside from Proclarix and relies on single-source third-party manufacturers.
• · The company stated its cash balance is not sufficient to fund operations for one year from the date of issuance of the March 31, 2026 financial statements.
• · Proclarix is intended for use in the diagnostic 'grey zone' where only 20-40% of men with elevated PSA present with clinically significant cancer.

12-08-2026

Intellus Advisors LLC filed its Form 13F-HR for the quarter ended June 30, 2026, reporting a total of 134 equity holdings with an aggregate market value of approximately $823.5 million. The portfolio is heavily weighted toward ETFs, with the top five holdings being Invesco QQQ Trust ($90.7M), Vanguard Dividend Appreciation ETF ($53.8M), American Century Quality Diversified International ETF ($51.5M), iShares Gold Trust ($44.5M), and Hartford Multifactor Developed Markets (ex-US) ETF ($42.5M). The filing does not provide prior-period comparisons, so period-over-period changes cannot be assessed.

• · The portfolio includes 134 equity holdings with a total market value of $823,494,157.
• · The top 10 holdings account for approximately $475 million, or 58% of the total portfolio.
• · The largest single stock positions are Alphabet Inc. Class A ($25.96M), Advanced Micro Devices ($25.81M), Apple Inc. ($24.02M), JPMorgan Chase ($20.63M), Broadcom ($17.03M), Eli Lilly ($16.00M), and Microsoft ($15.71M).
• · The portfolio includes a mix of ETFs, individual equities, and closed-end funds, with a notable tilt toward technology and dividend-focused strategies.
• · Gold-related holdings (iShares Gold Trust, Franco-Nevada, Wheaton Precious Metals, SPDR Gold Shares) total approximately $64.5M, or about 7.8% of the portfolio.
• · Smaller positions include speculative names such as SoFi Technologies ($2.75M), Palantir Technologies ($2.40M), Roblox ($345K), and Precigen ($90K).
• · The filing does not provide prior-quarter comparisons, so changes in holdings or market values cannot be determined.

12-08-2026

Datavault AI Inc. (DVLT) filed an S-3 shelf registration statement on August 12, 2026, registering up to 11,327,869 shares of common stock for resale by selling stockholder EOS Holdings. The filing also discloses a new class action lawsuit filed on August 5, 2026, alleging securities fraud violations from September 2024 to October 2025, which the company believes is without merit. Additionally, the company has significant outstanding dilution risk with over 854 million shares outstanding and numerous warrants and convertible notes, while also facing potential cash obligations under earnout agreements with EOS Holdings.

• · Class action lawsuit filed August 5, 2026 in Eastern District of Pennsylvania (Case No. 2:26-cv-05548-JS) alleging violations of Section 10(b) and 20(a) of the Exchange Act
• · Company changed name from WiSA Technologies to Datavault AI on February 13, 2025 after acquiring assets from EOS Holdings on December 31, 2024
• · EOS Holdings has a Cash Reversion Right to require cash payment if registration statement is not effective by applicable Outside Effectiveness Date
• · Exchange Cap limits share issuance to EOS Holdings unless stockholder approval is obtained
• · Outstanding warrants with exercise prices ranging from $0.6325 to $66,900 per share
• · Company will not receive any proceeds from the resale of shares by the selling stockholder
• · Principal executive office located at One Commerce Square, 2005 Market Street, Suite 2400, Philadelphia, PA 19103

12-08-2026

EWSB Bancorp, Inc. reported a net loss of $314,524 for Q2 2026 and $679,304 for H1 2026, compared to losses of $278,660 and $847,301 in the prior-year periods. Net interest income improved 8.7% in Q2 and 15.0% in H1, driven by lower interest expense and higher noninterest income, but the company remained unprofitable. Total assets declined 1.8% to $265.98 million, while total deposits grew 3.5% to $224.86 million, and the company raised $2.41 million in a stock offering during Q2.

• · EPS was -$0.44 for Q2 2026 vs -$0.40 in Q2 2025; -$0.96 for H1 2026 vs -$1.21 in H1 2025.
• · Provision for credit losses increased to $49,301 in Q2 2026 from $15,373 in Q2 2025, but decreased to $102,194 in H1 2026 from $125,663 in H1 2025.
• · Noninterest income rose 11.2% in Q2 and 20.9% in H1, driven by higher gain on sale of mortgage loans ($102,195 in Q2 vs $57,311; $260,930 in H1 vs $115,170).
• · Noninterest expense declined slightly: Q2 $1,892,374 vs $1,897,391; H1 $3,803,635 vs $3,865,916.
• · FDIC insurance premiums nearly doubled: $140,232 in Q2 2026 vs $73,910 in Q2 2025; $240,127 in H1 2026 vs $130,536 in H1 2025.
• · Cash and cash equivalents surged to $6,681,903 at June 30, 2026 from $1,272,620 at December 31, 2025.
• · Borrowed funds decreased to $23,417,549 from $38,368,820, reflecting repayment of $20 million in FHLB long-term advances.
• · Total gross write-offs year-to-date were $53,717, all in marine and recreational loans.
• · Nonperforming loans totaled $141,130 (one-to-four family residential $72,901; marine and recreational $68,229).
• · Accumulated other comprehensive loss improved to -$4,848,525 from -$5,108,963.
• · The company issued 261,682 common shares in Q2 2026, raising $2,407,963 net of issuance costs.

12-08-2026

AIR INDUSTRIES GROUP reported a net loss of $846,000 for Q2 2026, widening from a $422,000 loss in Q2 2025, while net sales declined 5.2% to $11.995M. Gross profit improved to $2.483M (20.7% margin) from $2.028M (16.0% margin), but operating expenses surged 41.0% to $2.849M, driving an operating loss of $366,000 versus a marginal profit of $8,000 a year ago. Customer concentration shifted, with RTX dropping from 44.3% to 25.4% of sales, while Lockheed Martin and Ontic increased their shares.

• · Customer concentration: Lockheed Martin 28.1% of net sales (2026) vs 27.5% (2025); RTX 25.4% vs 44.3%; Ontic 10.8% vs 2.5%.
• · Inventory breakdown as of June 30, 2026: Raw Materials $6.641M, Work In Progress $19.815M, Semi-Finished Goods $9.503M, Final-Finished Goods $0.740M.
• · Cash provided by operating activities for H1 2026 was $0.225M, down from $1.870M in H1 2025.
• · Capital expenditures for H1 2026 were $0.485M, down from $2.113M in H1 2025.
• · Net cash provided by financing activities was $0.274M in H1 2026 vs. $0.003M used in H1 2025.
• · Weighted average shares outstanding increased to 4,809,394 (Q2 2026) from 3,731,335 (Q2 2025).
• · Accumulated deficit widened to $72.278M as of June 30, 2026 from $70.412M at December 31, 2025.

12-08-2026

Ashford Hospitality Trust reported Q2 2026 results with Comparable RevPAR up 6.6% to $155.7, driven by a 5.8% increase in ADR and 0.7% occupancy growth. Net income attributable to common stockholders was $120.7 million ($1.62 per diluted share), while Adjusted EBITDAre reached $69.4 million. However, the company continues to suspend preferred dividends and redemptions due to cash constraints from debt repayment priorities, and interest rate headwinds persist.

• · Comparable Hotel EBITDA margin expanded 158 basis points to 32.5%.
• · Total debt decreased $599.5M (23.3%) from $2.6B at Dec 31, 2025 to $2.0B at June 30, 2026.
• · Blended average interest rate on total loans was 8.2% at June 30, 2026, with 94% floating-rate debt.
• · The Highland refinancing released 14 hotels from a cash sweep that had been in effect for more than a year.
• · Preferred dividends remain suspended; dividends are cumulative and will continue to accumulate while suspended.
• · The company noted that the probability of interest rate hikes has risen considerably, working against future capital returns.
• · Net working capital at quarter end was $83.8M.
• · CapEx invested during the quarter was $20.7M.
• · The nine hotel sales closed during Q2 2026 are expected to result in anticipated capital expenditure savings of $90.8M.
• · The Highland refinancing has a two-year initial term, interest only, bearing SOFR + 5.24% (improved from SOFR + 5.47% on prior loan).

12-08-2026

Trustmark Bank Trust Department filed its Form 13F-HR for the quarter ended June 30, 2026, reporting total holdings of approximately $1.68 billion across 360 equity positions. The portfolio is heavily weighted toward large-cap U.S. equities and fixed-income ETFs, with top holdings including iShares Core US Aggregate Bond ETF ($95.9M), iShares MSCI EAFE ETF ($65.2M), and iShares S&P 500 Value ETF ($18.2M). The filing reflects a diversified institutional portfolio with no single equity position exceeding 6% of total assets, indicating a conservative, income-oriented strategy.

• · The filing is for the period ending June 30, 2026, filed on August 12, 2026.
• · All positions are reported as sole voting and dispositive power unless otherwise noted as 'DFND' (defined as held in trust or fiduciary capacity).
• · The largest single position is iShares Core US Aggregate Bond ETF at $95.9M (969,210 shares).
• · The second-largest position is iShares MSCI EAFE ETF at $65.2M (627,719 shares).
• · Notable equity holdings include Apple Inc. ($30.6M), Alphabet Inc. Class A ($13.0M), Amazon.com Inc. ($14.4M), and Berkshire Hathaway Class B ($9.9M).
• · The portfolio includes a mix of domestic and international equities, fixed-income ETFs, sector-specific ETFs, and commodity ETFs (gold, silver).
• · No period-over-period comparisons are available as this is a single-quarter filing without prior quarter data.

12-08-2026

Enovix Corp filed an 8-K on August 12, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). The filing discloses financial results for the period ended June 28, 2026. No specific financial figures (revenue, EPS, etc.) were included in the filing summary; key quantitative data is NOT_DISCLOSED. The filing appears to be a routine earnings announcement, but without specific metrics, the overall performance direction cannot be assessed. Investors will need to review the full exhibit to evaluate revenue growth, profitability changes, or any forward guidance.

• · Filing date: August 12, 2026.
• · Period covered: Quarter ended June 28, 2026.
• · No specific financial data (revenue, EPS, guidance) mentioned in the filing summary.
• · The 8-K is a standard earnings-related filing; no other material events (e.g., acquisitions, leadership changes) indicated.